Citigroup Maintains Buy on Alpha Tau Medical, Raises Price Target to $9
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $7 to $9.
Citigroup analyst Yigal Nochomovitz maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $7 to $9.